drugset / Trial / NCT00942422
Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma
Phase 2
Terminated
8 enrolled
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Green tea extract contains ingredients that may prevent or slow the growth of monoclonal gammopathy of undetermined significance and/or smoldering multiple myeloma. PURPOSE: This phase II trial is studying how well green tea extract works in treating patients with monoclonal gammopathy of undetermined significance and/or smoldering multiple myeloma.
Timeline
- Start
- 2009-11
- Primary completion
- 2012-03
- Completion
- 2012-03
Outcome
Outcome not reported
Stopped (Enrollment): “Low accrual and early termination”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sinecatechins | Unknown | 800 mg | Oral |